Transdermal Glucose-Control Agent Composition for Sustained Skin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacotherapy for obesity and metabolic disorders, such as type 2 diabetes and dyslipidemia, faces challenges with conventional administration routes like pills or injections, leading to poor bioavailability, variable absorption rates, and systemic side effects, hindering the clinical translation of promising therapeutic agents like CB1 receptor antagonists and GLP-1 receptor agonists.
Innovation Solution
A transdermal delivery composition comprising a therapeutic effective amount of glucose controlling agents, a polymer component for sustained release, a penetrant component for skin penetration, a surfactant component for stabilization, and water, which includes CB1 receptor antagonists, GLP-1 receptor agonists, or SGLT-2 receptor antagonists, to provide sustained and prolonged release through the skin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional administration routes (pills or injection) are used, then therapeutic agents can be delivered to treat obesity and metabolic disorders, but bioavailability is poor and systemic side effects occur
Solution Approach 1:
The patent applies local quality by targeting adipose tissue specifically through transdermal delivery to subcutaneous fat deposits, rather than systemic distribution. The composition is designed to penetrate locally into adipose tissue where CB1 receptors are expressed, providing targeted therapeutic effect while minimizing systemic exposure and associated side effects.
Solution Approach 2:
The patent uses an intermediary approach by employing a transdermal delivery composition as a mediator between the therapeutic agent and the target tissue. This composition includes penetration enhancers and formulation components that facilitate the transport of glucose controlling agents through the skin barrier into adipose tissue, improving bioavailability while controlling systemic distribution.
2Reliability
If conventional administration routes are used, then therapeutic agents can be delivered, but absorption rates are variable
Solution Approach 1:
The patent implements continuity of useful action through sustained release formulation designed to provide consistent absorption over an extended period. The transdermal composition maintains stable release rates by controlling the diffusion and penetration of therapeutic agents continuously through the skin into adipose tissue, eliminating the variability associated with conventional dosing routes.
3Ease of operation
If transdermal delivery is used, then targeted delivery to adipose tissue is achieved, but the composition must overcome skin barrier penetration challenges
Solution Approach 1:
The patent employs penetration enhancers as intermediary substances that facilitate the transport of therapeutic agents through the skin barrier. These additives modify the skin stratum corneum properties or form temporary channels, enabling the glucose controlling agents to penetrate effectively into adipose tissue while maintaining the targeted delivery advantage.
Solution Approach 2:
The patent applies parameter changes by modifying the physical and chemical properties of the formulation to enhance penetration. This includes adjusting pH, adding penetration enhancers, optimizing lipid solubility, and controlling molecular size of the therapeutic agents to facilitate effective skin penetration while maintaining targeted delivery to adipose tissue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transdermal delivery system offers targeted and sustained delivery to adipose tissue, minimizing systemic exposure and side effects, with consistent and prolonged release of active ingredients over 4 to 12 hours, enhancing therapeutic efficacy for obesity and metabolic disorders.
Implementation Method 1
a penetrant component in an amount sufficient to assist with a transdermal penetration of the at least one glucose controlling agent through the skin tissue
Implementation Method 2
a surfactant component in an amount sufficient to stabilize the polymer adduct and release the at least one glucose controlling agent from the transdermal delivery composition
Implementation Method 3
a polymer component in an amount sufficient to hold the at least one glucose controlling agent and provide a sustained release of the at least one glucose controlling agent
Data Source
AI summary
A transdermal delivery composition including: a therapeutic effective amount of at least one glucose controlling agent; a polymer component in an amount sufficient to hold the at least one glucose controlling agent and provide a sustained release of the at least one glucose controlling agent from the transdermal composition after application to skin tissue; a penetrant component in an amount sufficient to assist with a transdermal penetration of the at least one glucose controlling agent; a surfactant component in an amount sufficient to stabilize the polymer adduct and release the at least one glucose controlling agent from the transdermal delivery composition after application to skin tissue; and water. Methods of delivery are provided.